Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients
Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustain...
Gespeichert in:
| Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2009-04, Vol.49 (4), p.1151-1157 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1157 |
|---|---|
| container_issue | 4 |
| container_start_page | 1151 |
| container_title | Hepatology (Baltimore, Md.) |
| container_volume | 49 |
| creator | Moucari, Rami Mackiewicz, Vincent Lada, Olivier Ripault, Marie‐Pierre Castelnau, Corinne Martinot‐Peignoux, Michelle Dauvergne, Agnes Asselah, Tarik Boyer, Nathalie Bedossa, Pierre Valla, Dominique Vidaud, Michel Nicolas‐Chanoine, Marie‐Hélène Marcellin, Patrick |
| description | Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on‐treatment serum HBsAg kinetics to predict SVR in HBeAg‐negative patients treated with PEG‐IFN. Forty‐eight consecutive patients were treated with PEG‐IFN (180 μg/week) for 48 weeks. Serum hepatitis B virus (HBV) DNA (COBAS TaqMan) and HBsAg (Abbott Architect HBsAg QT assay) were assessed at baseline, during treatment (weeks 12, 24, and 48), and during follow‐up (weeks 72 and 96). SVR was defined as undetectable serum HBV DNA ( |
| doi_str_mv | 10.1002/hep.22744 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67111522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67111522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4544-113a9730c8b09286ccc7170a67ebcb0508b277c4d1b55516b65331a510bff4df3</originalsourceid><addsrcrecordid>eNp10L2O1DAUBWALgdhhoeAFkBuQtsiuf-J4QjesBgZpJSigjhznOhh54uDrLJqOnmafkSfB7Iygorqy9ekc6RDynLNLzpi4-gLzpRC6rh-QFVdCV1Iq9pCsmNCsarlsz8gTxK-MsbYW68fkjLe8OCFW5OfWpHCgCGnZ090b3Ix0SHF-TTcUc4rTSOcEg7c5JhodxQWz8RMM9NanGOLorQk0Ac5xQqA50hnGQzC5CD9lSA5KCDXBmV8_7oQpn6UFNmN5TTCa7G-BzuXAlPEpeeRMQHh2uufk89vtp-tddfPh3fvrzU1la1XXFefStFoyu-5ZK9aNtVZzzUyjobc9U2zdC61tPfBeKcWbvlFScqM4652rByfPyatj7pzitwUwd3uPFkIwE8QFu0bz-3kKvDhCmyJiAtfNye9NOnScdX-W78ry3f3yxb44hS79HoZ_8jR1AS9PwGAZzSUzWY9_neCSyYY3xV0d3Xcf4PD_xm63_Xis_g0e_Z0E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67111522</pqid></control><display><type>article</type><title>Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Moucari, Rami ; Mackiewicz, Vincent ; Lada, Olivier ; Ripault, Marie‐Pierre ; Castelnau, Corinne ; Martinot‐Peignoux, Michelle ; Dauvergne, Agnes ; Asselah, Tarik ; Boyer, Nathalie ; Bedossa, Pierre ; Valla, Dominique ; Vidaud, Michel ; Nicolas‐Chanoine, Marie‐Hélène ; Marcellin, Patrick</creator><creatorcontrib>Moucari, Rami ; Mackiewicz, Vincent ; Lada, Olivier ; Ripault, Marie‐Pierre ; Castelnau, Corinne ; Martinot‐Peignoux, Michelle ; Dauvergne, Agnes ; Asselah, Tarik ; Boyer, Nathalie ; Bedossa, Pierre ; Valla, Dominique ; Vidaud, Michel ; Nicolas‐Chanoine, Marie‐Hélène ; Marcellin, Patrick</creatorcontrib><description>Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on‐treatment serum HBsAg kinetics to predict SVR in HBeAg‐negative patients treated with PEG‐IFN. Forty‐eight consecutive patients were treated with PEG‐IFN (180 μg/week) for 48 weeks. Serum hepatitis B virus (HBV) DNA (COBAS TaqMan) and HBsAg (Abbott Architect HBsAg QT assay) were assessed at baseline, during treatment (weeks 12, 24, and 48), and during follow‐up (weeks 72 and 96). SVR was defined as undetectable serum HBV DNA (<70 copies/mL) 24 weeks after treatment cessation. Twenty‐five percent of patients achieved SVR. They were not different from those who failed treatment regarding age, sex, ethnicity, HBV genotype, baseline serum HBV DNA and HBsAg levels, or liver histology. During treatment, serum HBsAg levels decreased only in patients who developed SVR, with mean decreases of 0.8 ± 0.5, 1.5 ± 0.6, and 2.1 ± 1.2 log10 IU/mL at weeks 12, 24, and 48, respectively. A decrease of 0.5 and 1 log10 IU/mL in serum HBsAg levels at weeks 12 and 24 of therapy, respectively, had high predictive values of SVR (negative predictive value [NPV] 90%, positive predictive value [PPV] 89% for week 12; NPV 97%, PPV 92% for week 24). HBsAg loss was observed in three patients, all with SVR. Conclusion: Early serum HBsAg drop has high predictive values of SVR to PEG‐IFN in HBeAg‐negative CHB patients. Serum quantitative HBsAg may be a useful tool to optimize the management of PEG‐IFN therapy in these patients. (HEPATOLOGY 2009.)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.22744</identifier><identifier>PMID: 19115222</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; DNA, Viral - blood ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis B e Antigens - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Humans ; Interferon-alpha - therapeutic use ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Polyethylene Glycols - therapeutic use ; Predictive Value of Tests ; Recombinant Proteins</subject><ispartof>Hepatology (Baltimore, Md.), 2009-04, Vol.49 (4), p.1151-1157</ispartof><rights>Copyright © 2008 American Association for the Study of Liver Diseases</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4544-113a9730c8b09286ccc7170a67ebcb0508b277c4d1b55516b65331a510bff4df3</citedby><cites>FETCH-LOGICAL-c4544-113a9730c8b09286ccc7170a67ebcb0508b277c4d1b55516b65331a510bff4df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.22744$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.22744$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21303616$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19115222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moucari, Rami</creatorcontrib><creatorcontrib>Mackiewicz, Vincent</creatorcontrib><creatorcontrib>Lada, Olivier</creatorcontrib><creatorcontrib>Ripault, Marie‐Pierre</creatorcontrib><creatorcontrib>Castelnau, Corinne</creatorcontrib><creatorcontrib>Martinot‐Peignoux, Michelle</creatorcontrib><creatorcontrib>Dauvergne, Agnes</creatorcontrib><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Boyer, Nathalie</creatorcontrib><creatorcontrib>Bedossa, Pierre</creatorcontrib><creatorcontrib>Valla, Dominique</creatorcontrib><creatorcontrib>Vidaud, Michel</creatorcontrib><creatorcontrib>Nicolas‐Chanoine, Marie‐Hélène</creatorcontrib><creatorcontrib>Marcellin, Patrick</creatorcontrib><title>Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on‐treatment serum HBsAg kinetics to predict SVR in HBeAg‐negative patients treated with PEG‐IFN. Forty‐eight consecutive patients were treated with PEG‐IFN (180 μg/week) for 48 weeks. Serum hepatitis B virus (HBV) DNA (COBAS TaqMan) and HBsAg (Abbott Architect HBsAg QT assay) were assessed at baseline, during treatment (weeks 12, 24, and 48), and during follow‐up (weeks 72 and 96). SVR was defined as undetectable serum HBV DNA (<70 copies/mL) 24 weeks after treatment cessation. Twenty‐five percent of patients achieved SVR. They were not different from those who failed treatment regarding age, sex, ethnicity, HBV genotype, baseline serum HBV DNA and HBsAg levels, or liver histology. During treatment, serum HBsAg levels decreased only in patients who developed SVR, with mean decreases of 0.8 ± 0.5, 1.5 ± 0.6, and 2.1 ± 1.2 log10 IU/mL at weeks 12, 24, and 48, respectively. A decrease of 0.5 and 1 log10 IU/mL in serum HBsAg levels at weeks 12 and 24 of therapy, respectively, had high predictive values of SVR (negative predictive value [NPV] 90%, positive predictive value [PPV] 89% for week 12; NPV 97%, PPV 92% for week 24). HBsAg loss was observed in three patients, all with SVR. Conclusion: Early serum HBsAg drop has high predictive values of SVR to PEG‐IFN in HBeAg‐negative CHB patients. Serum quantitative HBsAg may be a useful tool to optimize the management of PEG‐IFN therapy in these patients. (HEPATOLOGY 2009.)</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Recombinant Proteins</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L2O1DAUBWALgdhhoeAFkBuQtsiuf-J4QjesBgZpJSigjhznOhh54uDrLJqOnmafkSfB7Iygorqy9ekc6RDynLNLzpi4-gLzpRC6rh-QFVdCV1Iq9pCsmNCsarlsz8gTxK-MsbYW68fkjLe8OCFW5OfWpHCgCGnZ090b3Ix0SHF-TTcUc4rTSOcEg7c5JhodxQWz8RMM9NanGOLorQk0Ac5xQqA50hnGQzC5CD9lSA5KCDXBmV8_7oQpn6UFNmN5TTCa7G-BzuXAlPEpeeRMQHh2uufk89vtp-tddfPh3fvrzU1la1XXFefStFoyu-5ZK9aNtVZzzUyjobc9U2zdC61tPfBeKcWbvlFScqM4652rByfPyatj7pzitwUwd3uPFkIwE8QFu0bz-3kKvDhCmyJiAtfNye9NOnScdX-W78ry3f3yxb44hS79HoZ_8jR1AS9PwGAZzSUzWY9_neCSyYY3xV0d3Xcf4PD_xm63_Xis_g0e_Z0E</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Moucari, Rami</creator><creator>Mackiewicz, Vincent</creator><creator>Lada, Olivier</creator><creator>Ripault, Marie‐Pierre</creator><creator>Castelnau, Corinne</creator><creator>Martinot‐Peignoux, Michelle</creator><creator>Dauvergne, Agnes</creator><creator>Asselah, Tarik</creator><creator>Boyer, Nathalie</creator><creator>Bedossa, Pierre</creator><creator>Valla, Dominique</creator><creator>Vidaud, Michel</creator><creator>Nicolas‐Chanoine, Marie‐Hélène</creator><creator>Marcellin, Patrick</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients</title><author>Moucari, Rami ; Mackiewicz, Vincent ; Lada, Olivier ; Ripault, Marie‐Pierre ; Castelnau, Corinne ; Martinot‐Peignoux, Michelle ; Dauvergne, Agnes ; Asselah, Tarik ; Boyer, Nathalie ; Bedossa, Pierre ; Valla, Dominique ; Vidaud, Michel ; Nicolas‐Chanoine, Marie‐Hélène ; Marcellin, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4544-113a9730c8b09286ccc7170a67ebcb0508b277c4d1b55516b65331a510bff4df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moucari, Rami</creatorcontrib><creatorcontrib>Mackiewicz, Vincent</creatorcontrib><creatorcontrib>Lada, Olivier</creatorcontrib><creatorcontrib>Ripault, Marie‐Pierre</creatorcontrib><creatorcontrib>Castelnau, Corinne</creatorcontrib><creatorcontrib>Martinot‐Peignoux, Michelle</creatorcontrib><creatorcontrib>Dauvergne, Agnes</creatorcontrib><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Boyer, Nathalie</creatorcontrib><creatorcontrib>Bedossa, Pierre</creatorcontrib><creatorcontrib>Valla, Dominique</creatorcontrib><creatorcontrib>Vidaud, Michel</creatorcontrib><creatorcontrib>Nicolas‐Chanoine, Marie‐Hélène</creatorcontrib><creatorcontrib>Marcellin, Patrick</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moucari, Rami</au><au>Mackiewicz, Vincent</au><au>Lada, Olivier</au><au>Ripault, Marie‐Pierre</au><au>Castelnau, Corinne</au><au>Martinot‐Peignoux, Michelle</au><au>Dauvergne, Agnes</au><au>Asselah, Tarik</au><au>Boyer, Nathalie</au><au>Bedossa, Pierre</au><au>Valla, Dominique</au><au>Vidaud, Michel</au><au>Nicolas‐Chanoine, Marie‐Hélène</au><au>Marcellin, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2009-04</date><risdate>2009</risdate><volume>49</volume><issue>4</issue><spage>1151</spage><epage>1157</epage><pages>1151-1157</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on‐treatment serum HBsAg kinetics to predict SVR in HBeAg‐negative patients treated with PEG‐IFN. Forty‐eight consecutive patients were treated with PEG‐IFN (180 μg/week) for 48 weeks. Serum hepatitis B virus (HBV) DNA (COBAS TaqMan) and HBsAg (Abbott Architect HBsAg QT assay) were assessed at baseline, during treatment (weeks 12, 24, and 48), and during follow‐up (weeks 72 and 96). SVR was defined as undetectable serum HBV DNA (<70 copies/mL) 24 weeks after treatment cessation. Twenty‐five percent of patients achieved SVR. They were not different from those who failed treatment regarding age, sex, ethnicity, HBV genotype, baseline serum HBV DNA and HBsAg levels, or liver histology. During treatment, serum HBsAg levels decreased only in patients who developed SVR, with mean decreases of 0.8 ± 0.5, 1.5 ± 0.6, and 2.1 ± 1.2 log10 IU/mL at weeks 12, 24, and 48, respectively. A decrease of 0.5 and 1 log10 IU/mL in serum HBsAg levels at weeks 12 and 24 of therapy, respectively, had high predictive values of SVR (negative predictive value [NPV] 90%, positive predictive value [PPV] 89% for week 12; NPV 97%, PPV 92% for week 24). HBsAg loss was observed in three patients, all with SVR. Conclusion: Early serum HBsAg drop has high predictive values of SVR to PEG‐IFN in HBeAg‐negative CHB patients. Serum quantitative HBsAg may be a useful tool to optimize the management of PEG‐IFN therapy in these patients. (HEPATOLOGY 2009.)</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19115222</pmid><doi>10.1002/hep.22744</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-9139 |
| ispartof | Hepatology (Baltimore, Md.), 2009-04, Vol.49 (4), p.1151-1157 |
| issn | 0270-9139 1527-3350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67111522 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antiviral Agents - therapeutic use Biological and medical sciences DNA, Viral - blood Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B e Antigens - blood Hepatitis B Surface Antigens - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Humans Interferon-alpha - therapeutic use Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Polyethylene Glycols - therapeutic use Predictive Value of Tests Recombinant Proteins |
| title | Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A05%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20serum%20HBsAg%20drop:%20A%20strong%20predictor%20of%20sustained%20virological%20response%20to%20pegylated%20interferon%20alfa%E2%80%902a%20in%20HBeAg%E2%80%90negative%20patients&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Moucari,%20Rami&rft.date=2009-04&rft.volume=49&rft.issue=4&rft.spage=1151&rft.epage=1157&rft.pages=1151-1157&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.22744&rft_dat=%3Cproquest_cross%3E67111522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67111522&rft_id=info:pmid/19115222&rfr_iscdi=true |